SNWV$18.02
Chart
Performance
Key Stats
AI SNWV Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldSANUWAVE Health, Inc. shows some positive performance and thematic potential in regenerative medicine, but faces significant financial challenges including consistent losses and negative equity. The stock exhibits high volatility and a lack of profitability, making it a speculative investment. Long-term viability depends on overcoming these financial hurdles and demonstrating sustainable revenue growth.
Thematic
The company operates in the growing field of regenerative medicine and wound care, leveraging noninvasive ultrasound technology. The market for these therapies is expanding, offering potential growth opportunities. However, the company's ability to capitalize on these themes is currently constrained by its financial performance and operational scale.
Fundamental
The company exhibits weak fundamental performance characterized by negative earnings, declining revenue in recent years, and a significantly negative equity position. While it has a substantial cash balance, its ability to achieve profitability and sustainable growth remains a major concern. The high debt level relative to its equity is also a risk factor.
Technical
The stock has shown strong recent performance (181.38% in 1 year, 66.59% YTD), indicating significant upward momentum. However, some indicators suggest caution. The price is trading below key moving averages (200-day EMA/SMA), and RSI is in the neutral territory, suggesting a mixed short-term outlook. The stock's trading volume is relatively low.
| Factor | Score |
|---|---|
| Regenerative Medicine Market Growth | 85 |
| Medical Device Innovation | 75 |
| Healthcare Sector Trends | 60 |
| Regulatory Landscape | 50 |
| Competitive Environment | 65 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Growth | 50 |
| Balance Sheet Health | 5 |
| Cash Flow | 60 |
| Debt Load | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume | 40 |
| Recent Performance | 85 |
| Support/Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Recent Performance
The stock has shown significant positive performance across multiple periods: 5D (+3.68%), 1M (+22.37%), 6M (+30.89%), YTD (+66.59%), and a remarkable 1Y (+181.38%). This indicates strong recent investor interest and positive price momentum.
Potentially Undervalued based on Price-to-Sales
The Price-to-Sales (PS) ratio for 2021 was 24.1, which has significantly decreased to 6.0 for 2024. While still high, this downward trend might suggest potential undervaluation if growth continues.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with a Net Income of -$31.372M in Q4 2024 and -$25.807M in Q4 2023. The net margin remains significantly negative (-96.1% in Q4 2024).
High Price-to-Sales Ratio
Despite a decreasing trend, the Price-to-Sales (PS) ratio remains high, especially on a quarterly basis (e.g., 32.4 in Q1 2025), indicating the stock is valued significantly above its current revenue generation.
Calendar
August 2025
11
Next Earnings Date
H: $
A: $
L: $
Profile
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds. It also markets PACE systems that use acoustic pressure shockwaves generated by pulsed acoustic cellular expression technology to converge at selected areas for wound and orthopedic applications under the dermaPACE, Profile, and orthoPACE brand names. The company was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Dominant player in medical aesthetics with its Allergan Aesthetics portfolio (Botox, Juvederm, CoolSculpting), directly competing with services historically offered by AIH in non-surgical aesthetics.
Weight: 95
Leading developer of minimally-invasive aesthetic medical technologies (e.g., body contouring, skin tightening, hair removal), a direct competitor in the aesthetic device market.
Weight: 93
Manufactures and markets laser and energy-based aesthetic systems for various skin and body treatments, a direct competitor in the aesthetic device market.
Weight: 92
Known for HydraFacial, a popular non-invasive skin treatment system that directly targets the aesthetic clinic market for skin health and enhancement.